دورية أكاديمية
Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali.
| العنوان: | Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. |
|---|---|
| المؤلفون: | Diarra B; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali, Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp., Decroo T; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Antwerp, Research Foundation Flanders, Brussels, Belgium., Somboro A; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Coulibaly G; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Tolofoudie M; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Kone M; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Degoga B; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Diallo F; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Togo ACG; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Sanogo M; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Sarro YS; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Cisse AB; Laboratoire National de Référence des Mycobactéries, Institut National de Recherche en Santé publique, Bamako, Mali., Kodio O; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Baya B; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Kone A; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Maiga M; Global Health, Northwestern University, Chicago, IL, USA., Dao S; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Maiga II; Laboratoire d´analyses Médicales et Hygiène Hospitalière du Centre Hospitalier Universitaire du Point-G, Bamako, Mali., Murphy RL; Laboratoire National de Référence des Mycobactéries, Institut National de Recherche en Santé publique, Bamako, Mali., Siddiqui S; Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Toloba Y; Service de Pneumo-phtisiologie du Centre Hospitalier Universitaire du Point-G, Bamako., Konate B; Programme National de Lutte contre la Tuberculose (PNLT), Ministère de la santé et des Affaires Sociales, Bamako, Mali., Diakite M; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Doumbia S; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Van Deun A; Independent Consultant, Leuven, Belgium., Rigouts L; Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium., Diallo S; University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., de Jong BC; Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp. |
| المصدر: | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2020 Aug 01; Vol. 24 (8), pp. 763-769. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Union Country of Publication: France NLM ID: 9706389 Publication Model: Print Cited Medium: Internet ISSN: 1815-7920 (Electronic) Linking ISSN: 10273719 NLM ISO Abbreviation: Int J Tuberc Lung Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Paris, France : The Union, c1997- |
| مواضيع طبية MeSH: | Mycobacterium tuberculosis*/genetics , Tuberculosis, Multidrug-Resistant*, Drug Resistance, Bacterial ; Fluoresceins ; Humans ; Mali ; Molecular Diagnostic Techniques ; Rifampin ; Sensitivity and Specificity ; Sputum |
| مستخلص: | BACKGROUND: Non-conversion on auramine smear microscopy indicates a lack of treatment response, possibly associated with initial rifampicin-resistant tuberculosis (RR-TB). However, dead bacteria still stain positive and may be detected. Fluorescein diacetate smear microscopy (FDA) shows live mycobacteria only. Therefore, we studied the potential of 2-month (2M) FDA for the identification of initial RR-TB. METHODS: Between 2015 and 2018, we enrolled new smear-positive pulmonary TB patients from five local centres in Bamako, Mali. After baseline screening, sputum samples were collected at 1M, 2M, 5M and 18M. We used rpo B sequencing to identify initial RR-TB. RESULTS: Of 1359 patients enrolled, 1019 (75%) had rpo B sequencing results. Twenty-six (2.6%, 95%CI: 1.7-3.7) had mutations conferring rifampicin resistance. Most frequent rpo B mutations were located at the codons Asp435Val (42.4%) and Ser450Leu (34.7%). Among patients with initial RR-TB, 72.2% were FDA-negative at 2M ( P = 0.2). The positive and negative predictive value of 5M FDA for culture-based failure was respectively 20.0% and 94.7%. CONCLUSION: FDA did not identify the majority of patients with initial RR-TB or culture-based failure. As the full spectrum of mutations identified on sequencing was identified using Xpert, our data support its rapid universal implementation in Mali. |
| معلومات مُعتمدة: | R01 AI110386 United States AI NIAID NIH HHS; D71 TW010428 United States TW FIC NIH HHS; D43 TW010350 United States TW FIC NIH HHS |
| المشرفين على المادة: | 0 (Fluoresceins) VJT6J7R4TR (Rifampin) YL39R93PRE (diacetylfluorescein) |
| تواريخ الأحداث: | Date Created: 20200911 Date Completed: 20210427 Latest Revision: 20210704 |
| رمز التحديث: | 20240628 |
| DOI: | 10.5588/ijtld.19.0698 |
| PMID: | 32912379 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1815-7920 |
|---|---|
| DOI: | 10.5588/ijtld.19.0698 |